Private Eylea HD 8mg (aflibercept high-dose) wet AMD injection cost UK 2026

What is Eylea HD and why does the 8mg dose matter?

Eylea HD is a higher-strength formulation of aflibercept, a recombinant fusion protein that binds vascular endothelial growth factor (VEGF-A and VEGF-B) and placental growth factor (PlGF). Standard Eylea contains 2mg aflibercept per 0.05ml; Eylea HD contains 8mg in 0.07ml at a 4-fold higher molar concentration. The active molecule is identical — only the dose, formulation buffer and injection volume change. The European Medicines Agency licensed the 8mg dose for neovascular AMD and diabetic macular oedema in late 2024, with UK MHRA marketing authorisation following and NICE technology appraisal recommending it as a cost-effective option through patient access schemes.

The clinical rationale for 8mg is straightforward: higher intra-vitreal drug concentration takes longer to fall below the therapeutic threshold for VEGF suppression, so the injection-free interval before disease re-activates is longer. In the PULSAR trial for wet AMD, 79% of patients on the 8mg q12 arm maintained 12-week dosing through week 48, and 77% of the q16 arm maintained 16-week dosing — intervals that are physiologically impossible with the 2mg dose, where pharmacokinetic studies suggest functional VEGF rebound by week 6-8 in most eyes.

Crucially, the 8mg dose was non-inferior on best-corrected visual acuity (BCVA) gain at 48 weeks (PULSAR primary endpoint), with comparable rates of intra-retinal and sub-retinal fluid resolution on OCT. This is the foundation of the ‘same vision, fewer visits’ positioning that NICE, retina specialists and patients are responding to. The PHOTON trial reproduced the result for diabetic macular oedema, with non-inferior BCVA at week 48 against 2mg aflibercept on the standard q8 schedule.

Practically, Eylea HD is given by intravitreal injection — the same procedure as any anti-VEGF agent. The patient lies or reclines in a clean-injection room, the surface of the eye is cleaned with dilute povidone-iodine, the lid is held open with a wire speculum, topical anaesthetic drops are instilled, and the consultant injects 0.07ml through the pars plana 3.5-4.0mm posterior to the limbus using a 30G needle. The injection itself takes seconds; total chair time including OCT, consent recheck and the brief post-injection IOP/visual confirmation is 25-35 minutes.

UK 2026 Eylea HD pricing, in detail

Below is a typical UK 2026 private fee structure for Eylea HD at a CQC-registered London medical retina centre. Prices vary by provider, by whether you are bundled or itemised, and by whether you have private medical insurance.

If you are weighing Eylea HD against other anti-VEGF options, compare to private Vabysmo (faricimab) wet AMD injection, private Lucentis (ranibizumab) injection, standard Eylea 2mg injection and, for geographic atrophy rather than wet AMD, private Izervay (avacincaptad pegol). See the corresponding diagnosis pages on wet AMD and diabetic macular oedema.

What a quality UK Eylea HD package should include

When you read a private quote for Eylea HD, check it explicitly covers each of the following — if any line is excluded you will pay it on top.

• Consultant medical retina specialist — GMC-registered consultant ophthalmologist with completed vitreoretinal or medical retina fellowship and a substantive NHS retina post; not a senior fellow alone.
• Genuine Eylea HD 8mg pre-filled syringe — Bayer/Regeneron-supplied 0.07ml pre-filled syringe with full UK MHRA traceability and intact cold-chain documentation.
• Same-week appointment — Wet AMD is sight-threatening; expect a consultation and OCT within 5-7 working days of contact, not 4 weeks.
• Heidelberg or Cirrus HD-OCT imaging on the day — Pre-injection OCT to confirm activity (intra-retinal or sub-retinal fluid, pigment epithelial detachment) and post-loading OCT to confirm fluid resolution.
• OCT-angiography on indication — Non-invasive imaging of the choroidal neovascular membrane — useful at diagnosis and on treatment change.
• Sterile clean-injection room with HEPA filtration — CQC-registered ophthalmic day-case room, not a generic clinic; positive-pressure HEPA filtration reduces airborne contaminants.
• Dilute povidone-iodine 5-10% surface prep — The single most evidence-based prophylactic step against endophthalmitis.
• Topical anaesthetic and lid speculum — Proxymetacaine plus oxybuprocaine or amethocaine; wire speculum to prevent lash contamination.
• Post-injection IOP check and visual confirmation — Immediate hand-movements or count-fingers vision confirmation; tonometry if symptomatic IOP spike.
• Safety net for endophthalmitis — Written 24/7 contact pathway to a vitreoretinal on-call surgeon and an out-of-hours route to vitreous tap and inject.
• Written treat-and-extend plan — Documented OCT-based extension protocol: q8 to q12 to q16 in 4-week increments if dry; pull back 4 weeks if recurrence.
• Bilateral pathway if needed — Many wet AMD patients develop second-eye disease; the package should accommodate bilateral same-day or alternating-eye injection.
• Transparent itemised invoice for insurer — Bupa/AXA/Aviva/Vitality/WPA need procedure codes (CCSD) and drug-by-batch detail; the clinic should issue this without prompting.

Evidence base — what the Eylea HD literature shows

The 8mg dose is one of the most thoroughly trialled anti-VEGF developments of the past decade, with consistent 96-week and now 2-year readouts.

• PULSAR (wet AMD, 2024) — Phase 3 RCT, 1,009 patients, randomised 1:1:1 to 2mg q8, 8mg q12 and 8mg q16; published Lancet 2024. 8mg arms non-inferior on BCVA at week 48; 79% maintained q12 and 77% maintained q16 dosing.
• PHOTON (DME, 2024) — Phase 3 RCT in diabetic macular oedema, 658 patients; 8mg q12/q16 non-inferior to 2mg q8 on BCVA at week 48.
• 96-week PULSAR readout — Extended dosing maintained at 96 weeks in >75% of eyes on q12 and ~70% on q16 with no new safety signal.
• NICE TA appraisal — NICE evaluated aflibercept 8mg under technology appraisal pathways for wet AMD and DME and accepted it as a cost-effective option through the Bayer patient access scheme.
• Royal College of Ophthalmologists guideline — RCOphth wet AMD clinical guideline supports treat-and-extend as a routine maintenance protocol after loading.
• Aflibercept molecular pharmacology — Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Reviews in Clinical Pharmacology.
• Real-world endophthalmitis rate — Pooled meta-analyses across all anti-VEGF agents place injection-related endophthalmitis at ~1 in 2,000-3,000 injections with strict dilute povidone-iodine prophylaxis.
• CATT and IVAN comparator trials — Foundational head-to-head data for ranibizumab versus bevacizumab informing modern anti-VEGF practice.
• Treat-and-extend evidence — Multiple TREX-style protocols (TREX-AMD, ALTAIR, ARIES) demonstrate non-inferior outcomes with fewer injections versus monthly or pro re nata dosing.
• HAWK and HARRIER (brolucizumab) — Comparator evidence for high-volume anti-VEGF; subsequent IOI signal reshaped how new high-dose agents are monitored.
• UK Macular Society patient outcomes data — Patient-reported outcomes after wet AMD treatment in the UK private and NHS pathways.

Eylea HD versus the other anti-VEGF options

Choosing between anti-VEGF agents in 2026 is no longer a binary question. Each agent offers a different combination of evidence, dosing interval, mechanism and price.

• Standard Eylea (aflibercept 2mg) — The benchmark molecule with a decade of safety data and q8 dosing after loading. Cheaper per dose than Eylea HD but typically requires more visits; identical safety profile.
• Vabysmo (faricimab 6mg) — Dual Ang-2/VEGF-A inhibitor licensed for wet AMD and DME with q12-q16 extension data from TENAYA/LUCERNE and YOSEMITE/RHINE. Direct alternative to Eylea HD; choice often comes down to clinician preference and prior response.
• Lucentis (ranibizumab 0.5mg) — Original anti-VEGF for wet AMD with extensive 15-year safety data; typically monthly or treat-and-extend q4-q12 dosing. Now usually reserved when newer agents fail or are contraindicated.
• Biosimilar ranibizumab — Several MHRA-licensed biosimilars (Byooviz, Ximluci, Ongavia) offer ranibizumab equivalents at lower drug cost; useful where insurer formularies dictate.
• Beovu (brolucizumab) — Compact molecule allowing high molar dose; affected by a post-marketing IOI/retinal vasculitis safety signal that has restricted clinical use.
• Off-label bevacizumab (Avastin) — Widely used internationally for cost reasons; not licensed for intraocular use in the UK and not offered on most private retina pathways.
• Photodynamic therapy with verteporfin — Reserved for polypoidal choroidal vasculopathy variants and chronic central serous chorioretinopathy; not first-line for typical wet AMD.
• Pegcetacoplan and avacincaptad (geographic atrophy) — Different disease (dry AMD with geographic atrophy) — not interchangeable with wet AMD anti-VEGF treatment.
• No treatment / observation — Untreated wet AMD progresses to disciform scar and central scotoma over 12-24 months in the majority of eyes; observation is rarely defensible once subretinal fluid or haemorrhage is documented.

Who is private Eylea HD the right choice for?

Eylea HD is licensed and clinically indicated for the conditions below, and the private pathway is particularly attractive when NHS treat-and-extend intervals are slipping.

• Newly diagnosed wet AMD — OCT or OCT-A confirming active choroidal neovascular membrane with intra-retinal or sub-retinal fluid; same-week loading injection is the priority.
• Established wet AMD on standard Eylea 2mg seeking longer intervals — Patients well-controlled but tired of 6-8 week visits often switch to Eylea HD specifically for q12-q16 dosing.
• Wet AMD with persistent fluid on shorter-interval 2mg dosing — The higher dose can resolve residual fluid in eyes that never fully dry on 2mg; switching trials support this.
• Diabetic macular oedema with vision loss <6/12 — PHOTON-supported indication; particularly useful in patients juggling diabetic clinic visits.
• Geographically distant from clinic — Patients in the South-East commuting to London benefit disproportionately from the q12/q16 schedule.
• Working-age wet AMD (rare but treatable) — Younger working-age patients with PCV or atypical wet AMD often prioritise fewer disruption days.
• Bilateral wet AMD — Bilateral disease doubles injection burden; halving the visit frequency materially improves quality of life.
• Patient on full anticoagulation — Anti-VEGF injection is safe to perform on warfarin, DOACs and dual antiplatelet therapy — no stop required.
• Recent insurer change with formulary access — Bupa, AXA, Aviva, Vitality and WPA all now cover aflibercept 8mg under wet AMD pathway codes; private cover often unlocks the agent before NHS funding.
• Anaesthesia-sensitive patients — Intravitreal injection is topical only; no general or regional anaesthesia required.
• Carers or working family with travel logistics — Fewer hospital days per year reduces the family carer footprint of treatment significantly.
• Post-cataract eyes with developing wet AMD — Many wet AMD diagnoses are made at routine post-cataract OCT; private pathway allows seamless continuation from the cataract surgeon to medical retina.

NHS versus private Eylea HD

Eylea HD is available on the NHS under NICE technology appraisal and the Bayer patient access scheme. Wet AMD is one of the more time-pressured eye conditions on the NHS because untreated activity over weeks erodes irrecoverable BCVA. The challenge in the NHS is not eligibility but capacity: anti-VEGF macular clinic slots are some of the most contested in ophthalmology, and a treat-and-extend interval that drifts from the OCT-recommended 8 weeks to 12 or 14 weeks because of clinic pressure undermines exactly the visual stability the regime is designed to maintain.

Private pathways solve the capacity problem. A first injection within 5-7 days of OCT diagnosis is realistic at most CQC-registered London retina centres, and the subsequent treat-and-extend rhythm is held strictly to the OCT-recommended interval (q12 or q16) once stability is achieved. For wet AMD in particular, the clinical case for paying privately is not the molecule (which is the same one the NHS provides) but the timing and the visit cadence.

Some patients use a hybrid pathway: initiate privately to ensure same-week loading, then transfer to NHS care once treat-and-extend is stable. This is reasonable provided the receiving NHS unit can honour the same q12 or q16 interval the private OCT data has demonstrated — if it cannot, the long-term gain is partially lost. Many patients in greater London elect to remain private throughout for this reason, particularly second-eye patients.

Private medical insurance and Eylea HD

All five major UK insurers — Bupa, AXA Health, Aviva, Vitality and WPA — cover Eylea HD on their standard pathways, subject to your specific policy benefits, excesses and pre-authorisation requirements. Wet AMD is generally treated as a chronic condition requiring ongoing care; check whether your policy is ‘full refund’ or capped per-condition and whether the chronic-condition exclusion applies. Bupa and AXA have direct settlement with most major retinal centres; Aviva and Vitality usually settle invoices on a per-episode basis. Pre-authorisation generally requires the consultant’s OCT report, evidence of activity (fluid or haemorrhage) and a documented treatment plan — the retina centre’s administrative team usually handles this on your behalf with one signed authorisation form.

Risks of intravitreal Eylea HD injection

Intravitreal anti-VEGF injection is one of the most-studied procedures in medicine; the absolute risks are low but not zero. The 8mg dose has a safety profile broadly comparable to 2mg aflibercept in pooled trial data.

• Endophthalmitis — ~1 in 2,000-3,000 injections with dilute povidone-iodine prophylaxis. Presents at 2-7 days post-injection with pain, vision loss and hypopyon; needs same-day vitreoretinal review and tap-and-inject.
• Sterile intraocular inflammation (IOI) — Mild anterior uveitis or vitritis in <1% of eyes; usually responds to topical steroid. Rare cases of retinal vasculitis reported across the anti-VEGF class.
• Sub-conjunctival haemorrhage — Painless red patch at the injection site; common (15-30%) and harmless, resolves over 1-2 weeks.
• Transient intraocular pressure spike — IOP can rise briefly after the 0.07ml volume injection; significant spike requiring intervention is rare with good chair-side technique.
• Floaters — Air or vitreous strand floaters are common immediately post-injection and settle within hours to days.
• Cataract progression — Theoretical lens-touch risk from a misdirected needle; vanishingly rare in experienced hands.
• Retinal detachment — <1 in 5,000 injections; presents with new flashes, floaters or curtain visual field defect.
• Retinal break or vitreous haemorrhage — Very rare; can result from needle trajectory error in eyes with pre-existing peripheral pathology.
• Arterial thromboembolic events (theoretical) — Pooled MACE rates across anti-VEGF trials are comparable to control, but caution remains in patients within 3 months of stroke or MI.
• Anaphylaxis to povidone-iodine — True iodine allergy is rare; chlorhexidine is the alternative prep but with less safety data.
• Geographic atrophy progression in dry AMD areas — Some long-term data raises questions about whether intensive anti-VEGF suppression accelerates GA in juxta-foveal regions — balanced against the benefit of preventing wet AMD vision loss.
• Discomfort during injection — Most patients describe a brief pressure sensation rather than pain; persistent discomfort in the 24h post-procedure suggests corneal abrasion from speculum or povidone-iodine, which settles with lubricants.
• Failure of disease response — A minority of eyes do not dry on 8mg dosing; the next step is usually switching anti-VEGF agent (typically to Vabysmo) rather than dose escalation.
• Patient adherence drop-off — The biggest real-world cause of vision loss in treated wet AMD is missed appointments; longer intervals only help if the patient still attends at week 16.

Recovery after an Eylea HD injection

There is no formal recovery period after intravitreal Eylea HD. Most patients are out of the chair within 30 minutes of arrival, drive home (the eye is not patched, but pupil-dilation drops may have been instilled, so most patients arrange a companion driver for the first injection), and resume normal activities the same day. Reading, screen work, light exercise and stairs are all unrestricted on day 1.

In the first 24 hours patients commonly notice a small dark floater (an air bubble or proteinaceous fragment from the injection), a foreign-body sensation in the eye from the povidone-iodine prep, and a bright red sub-conjunctival haemorrhage at the injection site. None of these is concerning; the floater settles within hours, the foreign-body sensation responds to preservative-free lubricants every 1-2 hours, and the haemorrhage clears over 1-2 weeks. Mild brow ache or a sense of pressure can persist for a few hours.

Activities to avoid for the first 48 hours: swimming, hot tubs, dusty environments and rubbing the eye. Showering and washing the face are fine, but try not to splash water directly into the eye. Eye make-up is best avoided for 48 hours. If you wear contact lenses, switch to glasses for the first 2 days.

Red-flag symptoms to escalate to the 24/7 clinic line immediately: progressively worsening vision over 1-3 days, increasing pain not relieved by simple analgesia, increasing redness, a hypopyon (visible white fluid level in the front of the eye), or new floaters, flashes or a curtain field defect at any point. Endophthalmitis is the headline concern at days 2-7; retinal detachment can present from days 0 to many weeks after injection.

The next milestone is your week 1-2 safety check (slit-lamp + IOP), followed by an OCT review at the planned treat-and-extend interval — typically 8 weeks after the third loading dose, with extension to 12 and then 16 weeks if the macula is dry on imaging.

How to choose a London clinic for Eylea HD

Anti-VEGF outcomes depend more on the system around the injection than on the injection itself. The following are the markers of a high-quality private retinal service.

• Consultant with a substantive medical retina post — Look for a GMC-registered consultant ophthalmologist with completed vitreoretinal or medical retina fellowship and an NHS post at Moorfields, the Western Eye Hospital, King's, the Royal Free or a comparable retina centre.
• CQC inspection rating — Check the Care Quality Commission report on the day-case unit; you want ‘Good’ or ‘Outstanding’ on Safe and Effective domains.
• Heidelberg Spectralis or Cirrus HD-OCT — These are the gold-standard OCT platforms for macular imaging; some clinics still run older Stratus or Cirrus 4000 series, which are usable but less reliable for fluid quantification.
• OCT-angiography availability — Useful for differentiating quiescent from active CNV; not essential at every visit but should be on the menu.
• Same-week appointment SLA — Wet AMD diagnosed today should be loaded within 5-7 working days, not 4 weeks.
• Dedicated clean-injection room — Separate from general clinic; HEPA-filtered ideally.
• Written treat-and-extend protocol — Ask to see the written protocol the clinic uses for q8-q12-q16 extension and pull-back; if there isn't one, the OCT data may not be driving your dosing.
• 24/7 vitreoretinal on-call route — There must be a written telephone pathway to a VR surgeon within hours of symptom onset for suspected endophthalmitis.
• Per-injection itemised billing — Helpful for insurer reconciliation and for understanding what you're paying for.
• Transparent year-1 and year-2 cost estimate — A clinic that can quote a likely year-1 and year-2 cost range is one that takes ownership of your longitudinal care; clinics that won't are usually pricing per-episode without thinking about the trajectory.
• Continuity of consultant — You want the same consultant to review your OCT each visit; locum-based pathways risk inconsistent interval decisions.

Frequently asked questions

Methodology and sources

This page is built from published phase 3 RCT data, UK regulatory documents, real-world meta-analyses and the practical experience of UK CQC-registered private retina services. Where prices are quoted they reflect typical UK 2026 self-pay rates observed across London medical retina centres at the time of publication.

• PULSAR (aflibercept 8mg in wet AMD): Lanzetta P et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration. The Lancet 2024.
• PHOTON (aflibercept 8mg in DME): Brown DM et al. Intravitreal aflibercept 8 mg for diabetic macular oedema. The Lancet 2024.
• PULSAR 96-week data: presented at AAO 2024 retina subspecialty sessions.
• Royal College of Ophthalmologists clinical guideline on age-related macular degeneration.
• NICE technology appraisal of aflibercept 8mg for wet AMD and DME (under the Bayer patient access scheme).
• European Medicines Agency Summary of Product Characteristics for Eylea HD (aflibercept 8mg/0.07ml).
• MHRA UK marketing authorisation and prescriber information for Eylea HD.
• American Academy of Ophthalmology Preferred Practice Pattern: Age-Related Macular Degeneration.
• Endophthalmitis prophylaxis evidence: Storey PP et al. on dilute povidone-iodine and post-injection antibiotic prophylaxis.
• TENAYA / LUCERNE (faricimab in wet AMD) phase 3 trials for comparator reference.
• Care Quality Commission inspection reports for London ophthalmic day-case providers.
• British and Eire Association of Vitreoretinal Surgeons (BEAVRS) practice standards.
• Macular Society UK patient information and outcome surveys.

This page is editorial and educational. It is not personalised medical advice. Suitability for Eylea HD, the choice of anti-VEGF agent, the loading regime and the treat-and-extend interval are individual decisions made between you and a GMC-registered consultant medical retina specialist following a full clinical assessment. Prices are typical UK 2026 ranges at CQC-registered London centres and may vary.

Book your London Eylea HD consultation

Wet age-related macular degeneration is time-critical. Same-week consultation at a CQC-registered London medical retina centre, OCT imaging on the day and same-week initiation of Eylea HD loading offers the best chance of preserving central vision. Our consultants are GMC-registered medical retina specialists with substantive NHS retina posts, completed VR/medical retina fellowships and Royal College of Ophthalmologists subspecialty training. Call us or use the appointment form.

Related reading: Private Vabysmo wet AMD injection · Private standard Eylea 2mg injection · Private Lucentis (ranibizumab) injection · Wet AMD condition guide · Diabetic macular oedema guide